Apollo to invest €3bn in pharmaceutical biz Bayer
- The transaction is a minority, non-controlling stake in a newly established entity holding Bayer’s long-acting reversible contraceptives business.
- The investment will support Bayer’s capital structure and provide additional flexibility for manging increased liquidity requirements.
Apollo has agreed to make a €3 billion minority investment in German multinational pharmaceutical and life sciences company Bayer.